CBD and Hemp Products in Poland: Legal Status and Potential Risks

CBD and Hemp Products in Poland: Legal Status and Potential Risks

CBD (cannabidiol) is a non-intoxicating cannabinoid that can be obtained from Cannabis sativa L., including industrial hemp varieties. Hemp products are goods made from industrial hemp, including oils, extracts, cosmetics, foods, and raw plant material. In Poland, the key legal issue is not marketing language but the product’s actual composition, THC content, and regulatory classification (food, supplement, cosmetic, medicinal product, or controlled substance).

cbd legal poland – the core rule: THC and regulatory classification

In Poland, “cbd legal poland” is not a single yes-or-no conclusion. Legal exposure usually depends on two parallel tracks:

• Controlled substance and drug-law risk – whether the material qualifies as industrial hemp (fiber hemp) and whether THC thresholds and cultivation/processing rules are met.
• Regulatory and consumer-law risk – whether the product is placed on the market lawfully as a food, supplement, cosmetic, or medicinal product, including labeling and claims.

The main criminal-law touchpoint is the Act of 29 July 2005 on Counteracting Drug Addiction (Ustawa o przeciwdziałaniu narkomanii) [1]. This act regulates, among others, what constitutes narcotic drugs, psychotropic substances, and “fiber hemp” (industrial hemp), and sets rules relevant to cultivation, processing, possession, and trading.

hemp law poland – industrial hemp vs cannabis: why the definition matters

Under hemp law Poland, industrial hemp (fiber hemp) is generally treated differently from cannabis intended for narcotic use. The differentiation is practical: enforcement bodies focus on THC content, plant parts and form (including flowers/inflorescences, biomass, extracts), and whether the product may be treated as material from which narcotic substances can be obtained.

For businesses, the definition matters because:

• Supply chain documentation must align with “industrial hemp” requirements.
• Any deviation in THC content or unclear origin can trigger seizure, laboratory testing, and operational disruption.
• Misclassification affects tax, customs, and consumer safety obligations.

cbd oil regulation – product categories and the most common compliance traps

CBD oils are marketed in Poland under different categories, and each category creates different obligations:

• Food – must comply with food law and safety rules.
• Food supplement – still a food category, but with additional presentation rules (no medicinal claims).
• Cosmetic – must comply with EU cosmetics rules, including safety assessment and product information file.
• Medicinal product – requires marketing authorization; therapeutic claims can push a product into this category.

From a risk perspective, the most frequent issues seen in cbd oil regulation are:

1. Unlawful health claims (suggesting treatment or prevention of disease) that can trigger regulatory action and, in some scenarios, criminal exposure if consumers are misled on a large scale.
2. Novel food exposure under EU rules. Cannabidiol (CBD) and CBD-rich extracts intended for ingestion are indicated in the EU Novel Food Catalogue as “novel,” and placing such products on the market generally requires prior authorization under Regulation (EU) 2015/2283 [2], unless a business can demonstrate a relevant history of consumption in the EU before 15 May 1997 for the specific product.
3. Mismatch between declared and actual content – laboratory results showing higher THC than declared, or inconsistent CBD levels, increasing enforcement interest.

cannabis products – where criminal and administrative risks overlap

Cannabis products in Poland can create a mixed risk landscape: administrative (inspections, withdrawals, fines) and criminal (seizure, charges, and reputational damage). The operational impact is often immediate: detained shipments, frozen sales channels, payment provider issues, and management time diverted to crisis response.

Possession, trading, and “THC surprise” as a real-life risk

Even when a business intends to sell compliant CBD products, the “THC surprise” scenario is common: a batch tests above the permitted level, or documentation is incomplete. This can lead to:

• Seizure of goods pending expert testing.
• Questioning of responsible persons (management, quality, logistics).
• Parallel proceedings: criminal case plus administrative actions (consumer protection, sanitary inspection, trade inspection).

Where authorities treat the material as a controlled substance, criminal-law assessments are made under the Act on Counteracting Drug Addiction [1] and, depending on the conduct, under the Criminal Code or Fiscal Penal Code (for customs and excise-related angles).

Import and customs exposure: documentation, labeling, and seizures

Cross-border movement of hemp and CBD goods brings additional scrutiny. Customs disputes typically revolve around classification, declared composition, and supporting documents (certificates of analysis, invoices, transport documents, specifications). If irregularities are suspected, consequences can include detention, administrative penalties, and in some cases criminal-fiscal proceedings.

For a practical overview of risk patterns in this area, see KKZ materials on customs violations and enforcement pathways.

Business controls that reduce risk in practice

Risk reduction is mainly operational, not theoretical. Companies handling hemp-derived goods typically benefit from controls in four areas:

• Supplier onboarding – contractual quality parameters, batch traceability, audit rights.
• Testing strategy – independent laboratory tests for THC/CBD per batch, with retention samples.
• Marketing and labeling review – controlling claims, avoiding medicinal positioning unless authorized.
• Incident response – procedures for inspections, seizures, and internal escalation.

In higher-risk scenarios, legal and forensic support can be combined, including evidence preservation, internal interviews, and review of communications to prevent secondary liability.

Criminal defense perspective: what authorities usually examine

When CBD or hemp goods become a criminal-law issue, enforcement bodies typically focus on:

1. Objective parameters – THC levels, type of material (flowers/inflorescences, extract), quantities, and intended use.
2. Knowledge and intent – whether responsible persons knew about non-compliance, ignored test results, or used misleading documentation.
3. Supply chain credibility – traceability, COAs, contracts, and transport records.
4. Commercial scale – distribution scope, repeated batches, and consumer impact.

In such cases, early evidence control matters: securing laboratory documentation, internal quality records, correspondence with suppliers, and customer-facing materials. More on enforcement dynamics and defense strategies is discussed in dedicated resources on drug-related offenses.

Three practical exceptions and clarifications

The legal qualification of CBD and hemp products is fact-dependent. Three recurring exceptions should be kept in mind:

1. Exception 1 – medicinal classification by claims or presentation: even a low-THC CBD oil may be treated as a medicinal product if it is presented as treating or preventing disease, which can trigger pharmaceutical-law consequences and product withdrawal requirements.
2. Exception 2 – “novel food” barrier for ingestible CBD: ingestible CBD products can fall under the EU novel food regime (Regulation (EU) 2015/2283) [2], meaning authorization may be required before legal placing on the market, regardless of THC content (subject to any proven pre-1997 consumption history for the specific product).
3. Exception 3 – criminal risk from batch-level non-compliance: even when a product line is designed to be compliant, a single batch exceeding permitted THC levels or lacking credible documentation may lead to seizure and allegations typically assessed under the Act on Counteracting Drug Addiction [1].

Related KKZ resources for further reading

• Drug offences – scope of criminal exposure and defense work
• Drug-related offenses in Poland – consequences and defense strategies
• Customs violations in Poland – criminal and administrative penalties

Kopeć & Zaborowski (KKZ) supports businesses and individuals in criminal cases and compliance projects where hemp and CBD supply chains create exposure across inspections, customs, and criminal proceedings.

If a case involves detention of hemp/CBD goods, allegations linked to controlled substances, or reputational risk from enforcement actions, it can be useful to consult the situation and discuss possible steps with a criminal lawyer. More information and contact options are available at https://criminallawpoland.com/contact/.

FAQ: CBD and Hemp Products in Poland: Legal Status and Potential Risks

1) Is CBD legal in Poland?

CBD itself is not treated as an intoxicant. Legal risk usually depends on THC content and whether the product is placed on the market in a compliant category (food, supplement, cosmetic, or medicinal product). Fact-specific assessment is required.

2) Can CBD oil be sold as a food supplement in Poland?

It may be possible only if the product complies with food law, labeling rules, and does not make medicinal claims. In practice, ingestible CBD products commonly raise “novel food” issues under Regulation (EU) 2015/2283 [2], which may require authorization unless a relevant pre-15 May 1997 history of consumption can be demonstrated for the specific product.

3) Are hemp flowers legal to sell in Poland?

This depends on the factual situation, including THC content, intended use, and whether the product may be treated as material usable for obtaining narcotic substances. Enforcement practice can be strict, and seizures for testing are a recurring scenario.

4) What happens if a CBD batch tests above the permitted THC level?

Goods can be detained or seized for expert testing. Depending on quantities and circumstances, responsible persons may face questioning and potential charges assessed under the Act on Counteracting Drug Addiction [1]. Administrative actions (withdrawal, fines) may also follow.

5) Can marketing claims create legal exposure even if THC is compliant?

Yes. Claims suggesting treatment or prevention of disease can push a product into the medicinal-product category and trigger regulatory action. Claims and labeling should be reviewed as carefully as composition.

6) What documents reduce risk during inspections or customs clearance?

Typically useful are certificates of analysis from reliable labs, batch traceability records, invoices and transport documents, product specifications, and compliant labeling files. Missing or inconsistent documentation increases the risk of detention and deeper investigation.

Bibliography

1. Act of 29 July 2005 on Counteracting Drug Addiction (Poland) – consolidated text available via ISAP (Sejm legal database).
2. Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods.
3. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
4. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.

This material is informational and does not constitute legal advice. The legal qualification of CBD and hemp products depends on the specific facts, including composition, documentation, and the way the product is marketed.

Weryfikowalne twierdzenia wychwycone w tekście (checklista)

• Definicje i właściwości: „CBD jest nieodurzające”; CBD pochodzi z Cannabis sativa L.; „hemp products” obejmują m.in. oleje/ekstrakty/kosmetyki/żywność/surowiec.
• Tezy prawne (Polska): kluczowe są: skład, THC i kwalifikacja (żywność/suplement/kosmetyk/lek/substancja kontrolowana); znaczenie ustawy z 29.07.2005 r.; rozróżnienie konopi włóknistych vs konopi „narkotycznych”; ryzyka: zatrzymania, badania, postępowania administracyjne i karne; możliwość kwalifikacji jako produkt leczniczy przez claims/presentation.
• Prawo UE: novel food (Rozp. 2015/2283) i praktyka kwalifikowania CBD do novel food; wymóg autoryzacji; kryterium historii spożycia przed 15.05.1997; kosmetyki (Rozp. 1223/2009); produkty lecznicze (Dyrektywa 2001/83/WE).
• Procedury/praktyka: kontrole celne opierają się o klasyfikację i dokumenty; znaczenie COA, faktur, dokumentów transportu; „najczęstsze” problemy (claims, novel food, rozbieżności składu) — twierdzenia trendowe bez danych liczbowych.

Uwaga metodyczna: W tekście nie było twardych liczb/progów THC ani stawek/terminów proceduralnych do punktowej weryfikacji. Najbardziej „twarde” elementy to akty prawne UE/PL oraz ogólne zasady kwalifikacji (novel food/lek/kosmetyk), które doprecyzowano minimalnie (data 15.05.1997 i odniesienie do EU Novel Food Catalogue jako źródła praktyki kwalifikacyjnej).